Introduction And Objectives: As erectile dysfunction is more commonly being diagnosed and treated with a preexisting inflatable penile prosthesis (IPP) insertion at younger ages, surgeons will increasingly encounter pre-placed abdominal reservoirs when performing pelvic surgery.

Materials And Methods: A 69-year-old Caucasian man with BCG refractory carcinoma-in-situ (CIS) and past history of non-invasive high-grade urothelial carcinoma of the bladder was a candidate for a radical cystectomy and an ileal-neobladder diversion. He had a three-components IPP inserted for the treatment of Peyronie disease and organic erectile dysfunction (ED). During the radical cystectomy the reservoir was encapsulated on the left lateral pelvic wall over the external iliac vessels. It was isolated and IPP was inflated to reduce the reservoir size. After accurate disinfection, the reservoir was removed from Retzius space without disconnecting it from the pump. Then, the radical cystectomy was carried out without any intraoperative complications and Studer ileal orthotopic neobladder was performed. At the end of the surgery, the reservoir was disinfected with the Mulcahy protocol and then placed in the same position.

Results: A week after catheter removal the IPP was successfully activated. The patient's postoperative recovery was uneventful and no postoperative complication occurred. Definitive histological examination described a multifocal urothelial carcinoma of the bladder: pG3Tis N0 R0. The patient reports excellent functionality of the penile prosthesis and is currently using it.

Conclusions: Sexual functionality preservation in oncologic patients should be pursued when possible. In this report, the functionality of the IPP was preserved, while still performing oncologically radical procedures. A multicenter study is needed to assure more solid recommendations on this rare procedure that is surely burdened by a lot of risks.

Download full-text PDF

Source
http://dx.doi.org/10.1177/03915603211033165DOI Listing

Publication Analysis

Top Keywords

radical cystectomy
16
penile prosthesis
12
orthotopic neobladder
8
inflatable penile
8
erectile dysfunction
8
urothelial carcinoma
8
carcinoma bladder
8
radical
5
ipp
5
cystectomy orthotopic
4

Similar Publications

A young, intact, female, American Bulldog was presented for hemorrhagic vaginal discharge. Anemia, thrombocytopenia, leukocytosis with neutrophilia, azotemia, and electrolyte disturbances were detected in the bloodwork. A urachal diverticulum with concurrent uterine distention was identified by ultrasonography and CT.

View Article and Find Full Text PDF

Previous maximal transurethral resection of bladder tumor lead to unfavorable perioperative outcomes following radical cystectomy.

Int Urol Nephrol

January 2025

Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cuiyingmen, Chengguan District, Lanzhou, Gansu, China.

Purpose: To evaluate the impact of maximal transurethral resection of bladder tumor (TURBT) on perioperative outcomes following radical cystectomy (RC).

Methods: This study included 310 patients who underwent RC for the diagnosis of bladder urothelial carcinoma. Of these, 146 patients had a history of maximal TURBT (TURBT group) and 164 did not (non-TURBT group).

View Article and Find Full Text PDF

: Diabetes mellitus (DM) is associated with worse surgical outcomes, and is a risk factor for bladder cancer and subsequent oncological outcomes. This study evaluated outcomes robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) in patients with DM. : Data of adults ≥ 18 years old with DM who underwent radical cystectomy were extracted from the United States National Inpatient Sample database 2005-2018.

View Article and Find Full Text PDF

Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma and muscle-invasive bladder cancer. This study evaluates the safety and efficacy of tislelizumab combined with low-dose nab-paclitaxel in extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC).

Patients And Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients with visually incomplete resection and/or high-volume high-grade T1 tumors (with or without carcinoma in situ), who were ineligible for or declined radical cystectomy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!